890 related articles for article (PubMed ID: 21821475)
1. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
[TBL] [Abstract][Full Text] [Related]
4. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
7. Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind.
van Wietmarschen N; Nussenzweig A
Mol Cell; 2018 Sep; 71(6):877-878. PubMed ID: 30241603
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
9. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
11. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors: its role in treatment of cancer.
Chen A
Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
[TBL] [Abstract][Full Text] [Related]
13. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
Metzger MJ; Stoddard BL; Monnat RJ
DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
[TBL] [Abstract][Full Text] [Related]
14. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
15. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
Croset A; Cordelières FP; Berthault N; Buhler C; Sun JS; Quanz M; Dutreix M
Nucleic Acids Res; 2013 Aug; 41(15):7344-55. PubMed ID: 23761435
[TBL] [Abstract][Full Text] [Related]
17. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
18. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
19. Role of PARP inhibitors in cancer biology and therapy.
Davar D; Beumer JH; Hamieh L; Tawbi H
Curr Med Chem; 2012; 19(23):3907-21. PubMed ID: 22788767
[TBL] [Abstract][Full Text] [Related]
20. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
